IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer
Tadashi Manabe(Keio University), Kenzo Soejima(Keio University), Toshiki Ebisudani(Keio University), Harumi Kagiwada(National Institute of Advanced Industrial Science and Technology), Keigo Kobayashi(Osaka Gakuin University), Keita Masuzawa(Kitasato Institute Hospital), Shinnosuke Ikemura(Keio University), Katsuhisa Horimoto(National Institute of Advanced Industrial Science and Technology), Yuichiro Hayashi(Keio University), Hideki Terai(Kitasato Institute Hospital), Koichi Fukunaga(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Junko Hamamoto(Keio University), Kazuhiko Fukui(National Institute of Advanced Industrial Science and Technology), Ichiro Kawada(Keio University)
Cited by 54
Related Papers
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
|Nature Medicine|2018|317
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker
|npj Digital Medicine|2020|112